| Literature DB >> 27048382 |
Mimi Tang1,2, Min Zhang1,2, Hualin Cai1, Huande Li3, Pei Jiang4, Ruili Dang4, Yiping Liu1, Xin He1,2, Ying Xue1,2, Lingjuan Cao1,2, Yanqin Wu1,2.
Abstract
BACKGROUND: Long-chain polyunsaturated fatty acids (PUFAs) are major components of the phospholipids that forming the cell membrane. Insufficient availability of PUFAs during prenatal period decreases accretion of docosahexaenoic acid (DHA) in the developing brain. DHA deficiency is associated with impaired attention and cognition, and would precipitate psychiatric symptoms. However, clinical studies on the potential benefits of dietary DHA supplementation to neural development have yielded conflicting results.Entities:
Keywords: Arachidonic acid (AA); Docosahexaenoic acid (DHA); Neurogenesis; Neurotransmitter system; Polyunsaturated fatty acids (PUFAs)
Mesh:
Substances:
Year: 2016 PMID: 27048382 PMCID: PMC4822267 DOI: 10.1186/s12944-016-0236-1
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1Maternal n-3 PUFAs deficiency decreases the neurogenesis in dentate gyrus (DG) region of neonatal hippocampus. BrdU was examined at the DG region by immunofluorescence (a); Quantification of BrdU at the DG region of neonatal hippocampus (one-way ANOVA, TUKEY post hoc test, *p < 0.05 vs. Control) (b). n = 5 in each group
Effects of maternal dietary (n-3) PUFA treatment on liver fatty acid composition of 1st-litter neonatal female rats
| FA | Percent of Total FA (area percent) | ||
|---|---|---|---|
| Deficient | Control | Supplementary | |
| C14:0 | 1.0 ± 0.1 | 1.0 ± 0. 0 | 1.0 ± 0.2 |
| C16:0 | 27.1 ± 0.5 | 26.3 ± 1.2 | 22. 3 ± 1.2* |
| C16:1 | 1.4 ± 0.1 | 1.6 ± 0.0 | 1.6 ± 0.2 |
| C18:0 | 6.7 ± 0. 4* | 9.5 ± 0.8 | 8.2 ± 0.6 |
| C18:1n9c | 11.6 ± 0.6** | 18.5 ± 0.8 | 12.6 ± 0.7** |
| C18:2n6c | 20.8 ± 1.3 | 16.6 ± 0.5 | 12.4 ± 0.9* |
| C18:3n3 | 0 | 0 | 0.8 ± 0. 1* |
| C20:4n6 | 16.8 ± 1.0* | 13.5 ± 0.5 | 6.1 ± 0.4** |
| C20:5n3 | 0 | 0.5 ± 0. 0 | 4.0 ± 0.5** |
| C24:0 | 3.0 ± 0.1** | 1.6 ± 0. 2 | 1.5 ± 0. 2 |
| C22:5n3 | 0 | 0 | 3.605 ± 0. 3* |
| C22:6n3 | 0.8 ± 0. 2* | 4.0 ± 0.5 | 11.1 ± 1.1** |
| Other MUFA | 1.7 ± 0. 1** | 2.6 ± 0. 1 | 1.9 ± 0. 1** |
| Other n-6 PUFA | 3.7 ± 0. 4* | 1.0 ± 0. 1 | 0 |
| Total n-3 PUFA | 0.7 ± 0. 2** | 3.9 ± 0.5 | 21.0 ± 0.2** |
| Total n-6 PUFA | 40.7 ± 1.6** | 30.7 ± 0. 4 | 18.8 ± 1.4** |
| n-3 PUFA/n-6 PUFA | 1.7 ± 0.6** | 12.7 ± 1.6 | 107.3 ± 7** |
| DHA/AA | 0.04 ± 0.01** | 0.31 ± 0.03 | 1.95 ± 0.08** |
Liver FA Composition was expressed as mean ± SEM (n = 5-6 per group). Data were analyzed by variance (ANOVA) for multiple comparisons followed by TUKEY or Dunnett’s t test for post-hoc test. ** p < 0.01, * p < 0.05 vs. Control
Effects of maternal dietary (n-3) PUFA treatment on whole brain fatty acid composition of 1st-litter neonatal female rats
| FA | Percent of Total FA (area percent) | ||
|---|---|---|---|
| Deficient | Control | Supplementary | |
| C14:0 | 2.4 ± 0.1 | 2.1 ± 0.2 | 2.5 ± 0.0 |
| C16:0 | 42.5 ± 1.3 | 39.7 ± 1.1 | 40.5 ± 0.5 |
| C16:1 | 3.0 ± 0.0 | 4.448 ± 0.1 | 4.5 ± 0.1 |
| C18:0 | 20.8 ± 0.4* | 19.7 ± 0.2 | 20.2 ± 0.1 |
| C18:1n9c | 12.1 ± 0.1** | 13.2 ± 0.1 | 13.7 ± 0.2* |
| C20:4n6 | 9.2 ± 0.3 | 9.4 ± 0.3 | 7.1 ± 0.5** |
| C22:6n3 | 0** | 5.3 ± 0.2 | 7.3 ± 0.3** |
| Other MUFA | 2.9 ± 0.0** | 3.1 ± 0.0 | 3.2 ± 0.1 |
| Other n-6 PUFA | 6.2 ± 0.2** | 1.5 ± 0.1 | 0 |
| Total n-3 PUFA | 0** | 5.2 ± 0.2 | 7.3 ± 0.4** |
| Total n-6 PUFA | 15.4 ± 0.5** | 10.7 ± 0.7 | 7.2 ± 0.5** |
| n-3 PUFA/n-6 PUFA | 0** | 49.2 ± 1.6 | 105.3 ± 10.2** |
| DHA/AA | 0** | 0.56 ± 0.02 | 1.07 ± 0.07** |
Brain FA Composition was expressed as mean ± SEM (n = 5-6 per group). Data were analyzed by variance (ANOVA) for multiple comparisons followed by TUKEY or Dunnett’s t test for post-hoc test. ** p < 0.01, * p < 0.05 vs. Control
The content of major neurotransmitters and their metabolites in whole brain of 1st-litter neonatal female rats
| Compound | Deficient | Control | Supplementary |
|---|---|---|---|
| GABA (ug/g) | 273.2 ± 7.29** | 225.0 ± 7.9 | 220.7 ± 14.1 |
| GLU (ug/g) | 604.8 ± 33.1 | 580.5 ± 56.2 | 550.7 ± 50.6 |
| GLN (ug/g) | 264.7 ± 18.1** | 422.1 ± 32.4 | 788.5 ± 53.2** |
| DA (ng/g) | 98.2 ± 10.8 | 106.4 ± 18.5 | 49.8 ± 4.5** |
| DOPAC (ng/g) | 4848.6 ± 286.9** | 3797.4 ± 178.8 | 4407.3 ± 221.5* |
| HVA (ng/g) | 11092.5 ± 963.5** | 7839.8 ± 908.1 | 9236.3 ± 988.0 |
| NE (ng/g) | 2026.9 ± 409.7 | 2240.3 ± 323.5 | 1046.8 ± 106.5** |
| MHPG (ng/g) | 2844.8 ± 185.3 | 2583.5 ± 245.3 | 2870.5 ± 225.2 |
| VMA(ng/g) | 18152.5 ± 1482.2** | 24125.9 ± 1439.0 | 26581.2 ± 1395.4 |
| TRY (ug/g) | 31.0 ± 1.9 | 30.8 ± 3.0 | 45.1 ± 3.4 |
| 5-HT (ng/g) | 215.9 ± 32.3 | 161.8 ± 20.9 | 169.2 ± 14.3 |
| 5-HIAA (ng/g) | 174.1 ± 19.2 | 223.8 ± 25.5 | 627.8 ± 41.7** |
| 5-HIAA/5-HT | 0.618 ± 0.1** | 1.745 ± 0.3 | 4.226 ± 0.6** |
| KYN (ng/g) | 507.2 ± 49.8 | 487.2 ± 35.6 | 626.0 ± 26.8** |
Data were expressed as mean ± SEM (n = 6-8per group). Data were analyzed by variance (ANOVA) for multiple comparisons followed by TUKEY or Dunnett’s t test for post-hoc test. ** p < 0.01, * p < 0.05 vs. Control
Fig. 2Effect of maternal diet of fatty acid on mRNA levels of the metabolizing enzymes of the neurotransmitters in brain of neonatal rat. Relative mRNA expression of GAD67 (a); Relative mRNA expression of GAD65 (b); Relative mRNA expression of GS (c); Relative mRNA expression of TPH2 (d); Relative mRNA expression of TH (e)
Fig. 3The correlation of FA composition and neurotransmitter concentration in brain of neonatal rat. The correlation of the level of AA and the content of GLN (a); The correlation of the level of AA and the content of 5-HIAA (b); The correlation of the level of AA and the ratio of 5-HIAA/5-HT (c); The correlation of the level of DHA and the content of GLN (d); The correlation of the level of DHA and the content of 5-HIAA (e); The correlation of the level of DHA and the ratio of 5-HIAA/5-HT (f); The correlation of the ratio of DHA/AA and the content of GLN (g); The correlation of the ratio of DHA/AA and the content of 5-HIAA (h); The correlation of the ratio of DHA/AA and the ratio of 5-HIAA/5-HT (i)
Fatty acid composition of the Experimental Diets
| Fatty acid | Content in diet(area percent) | ||
|---|---|---|---|
| Deficient | Control | Supplementary | |
| C16:0 | 6.61 | 11.18 | 9.96 |
| C18:0 | 2.31 | 3.17 | 3.39 |
| C18:3n3 | ND | 4.26 | 3.67 |
| C18:1n9c | 11.71 | 24.52 | 22.72 |
| C18:2n6c | 79.38 | 55.39 | 47.30 |
| C20:5n3 | ND | ND | 7.32 |
| C22:6n3 | ND | ND | 4.00 |
| Other MUFA | ND | 1.48 | 1.95 |
Diet fatty acid composition was determined by GC/MS using Supelco 37 Standard. ND: Not detected
Primer sequences used for the real-time PCR analysis
| Gene (accession no.) | Sense Primer (5’-3’) | Antisense Primer (5’-3’) | Amplicon length |
|---|---|---|---|
| GAD65 (NM_012563.1) | CAGCCTGTGAAGGAGAAAGG | GGTCTGCCAATTCCCAATTA | 159 bp |
| GAD67 (M76177.1) | CTGGAGCTGGCTGAATACCT | TCGGAGGCTTTGTGGTATGT | 146 bp |
| TPH2 (NM_173839.2) | GGGTTACTTTCCTCCATCGGA | AAGCAGGTTGTCTTCGGGTC | 119 bp |
| GS (M29579.1) | CCACTGTCCCTGGGCTTAGTTTA | AGTGACATGCTAGTCCCACCAA | 85 bp |
| TH (NM_012740.3) | CTCCTCACCTATGCATTCAC | TCCAATGTCCTGGGAGAACT | 105 bp |
| β-Actin (NM031144) | CATCCTGCGTCTGGACCTGG | TAATGTCACGCACGATTTCC | 116 bp |